Financial reports
10-Q
2024 Q2
Quarterly report
20 Feb 24
NT 10-Q
Notice of late quarterly filing
14 Feb 24
10-Q
2024 Q1
Quarterly report
14 Nov 23
10-K
2023 FY
Annual report
28 Sep 23
10-Q
2023 Q3
Quarterly report
17 May 23
NT 10-Q
Notice of late quarterly filing
15 May 23
10-Q
2023 Q2
Quarterly report
8 Feb 23
10-Q
2023 Q1
Quarterly report
9 Nov 22
10-K
2022 FY
Annual report
28 Sep 22
10-Q
2022 Q3
Quarterly report
12 May 22
Current reports
8-K
Entry into a Material Definitive Agreement
21 Jan 22
8-K
The patent relates to the administration of a specific composition comprised of cannabinoids to a patient
14 Jul 20
8-K
Departure of Directors or Certain Officers
6 Apr 20
8-K
Departure of Directors or Certain Officers
22 Oct 19
8-K
Regulation FD Disclosure
18 Jul 19
8-K
Departure of Directors or Certain Officers
3 Apr 19
8-K
Submission of Matters to a Vote of Security Holders
29 Mar 19
8-K
Regulation FD Disclosure
8 Mar 19
8-K
Nexien BioPharma Announces Acceptance of Patent Application No. 238946 by Israeli Patent Office
5 Mar 19
8-K
Nexien BioPharma to File Pre-IND Meeting Request with the FDA
26 Feb 19
Registration and prospectus
S-1/A
IPO registration (amended)
19 Jun 18
S-1/A
IPO registration (amended)
11 Jun 18
S-1
IPO registration
7 Jun 18
DRSLTR
Correspondence regarding draft registration statement
16 May 18
DRS/A
Draft registration statement (amended)
16 May 18
DRS/A
Draft registration statement (amended)
4 Apr 18
DRSLTR
Correspondence regarding draft registration statement
4 Apr 18
DRS
Draft registration statement
22 Jan 18
DRSLTR
Correspondence regarding draft registration statement
19 Jan 18
D
$1.26M in equity / securities to be acquired, sold $45.2K, 2 investors
8 Dec 17
Other
EFFECT
Notice of effectiveness
28 Jun 18
CORRESP
Correspondence with SEC
25 Jun 18
CORRESP
Correspondence with SEC
19 Jun 18
UPLOAD
Letter from SEC
15 Jun 18
UPLOAD
Letter from SEC
18 Apr 18
UPLOAD
Letter from SEC
20 Feb 18
UPLOAD
Letter from SEC
5 Oct 17
CORRESP
Correspondence with SEC
25 Sep 17
UPLOAD
Letter from SEC
30 Aug 17
CORRESP
Correspondence with SEC
16 Aug 17